Compare Guardant Health Inc. Common Stock (GH) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs L3Harris Technologies Inc — how do they compare? Guardant Health Inc. Common Stock trades at $168.44 (market cap $22.22B), while L3Harris Technologies Inc trades at $235.81 (market cap $44.12B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 0 Days and L3Harris Technologies Inc for 55 Days on average.
| GH | LHX | |
|---|---|---|
Market Cap | $22.22B | $44.12B |
Volume | 1,589,453 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $187.22 | $378.48 |
52-Week Low | $61.73 | $233.63 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $22.86B | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LHX trades at $233.63, down 1.79% for the day, amid bearish technical signals but strong fundamental performance. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.13 exceeding the $2.80 estimate. Recent contract wins totaling over $10 billion for THAAD and PAC-3 MSE propulsion systems provide substantial revenue visibility, while analyst consensus remains strongly bullish with a $340 price target representing 45% upside potential.
The investment case balances strong defense contracting fundamentals against technical weakness and legal overhangs. While operational performance and contract backlog support long-term growth, multiple law firm investigations create near-term uncertainty. The stock's current valuation at 23.93x P/E appears reasonable given projected 8.11% net margins and defense budget tailwinds, but requires monitoring of legal developments and execution on major contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
